Clinical Progression of Baseline Risk States for Mild Cognitive Impairment.
Cognitive decline
mild cognitive impairment
neurocognitive tests
risk factors
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
6
7
2022
medline:
24
8
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
This memory-clinic study joins efforts to study earliest clinical signs and symptoms of Alzheimer's disease and related dementias: subjective reports and objective neuropsychological test performance. The memory-clinic denoted two clinical "grey zones": 1) subjective cognitive decline (SCD; n = 107) with normal objective test scores, and 2) isolated low test scores (ILTS; n = 74) without subjective complaints to observe risk for future decline. Initial and annual follow-up clinical research evaluations and consensus diagnosis were used to evaluate baseline characteristics and clinical progression over 2.7 years, compared to normal controls (NC; n = 117). The ILTS group was on average older than the NC and SCD groups. They had a higher proportion of people identifying as belonging to a minoritized racial group. The SCD group had significantly more years of education than the ILTS group. Both ILTS and SCD groups had increased risk of progression to mild cognitive impairment. Older age, minoritized racial identity, and baseline cognitive classification were risk factors for progression. The two baseline risk groups look different from each other, especially with respect to demographic correlates, but both groups predict faster progression than controls, over and above demographic differences. Varied presentations of early risk are important to recognize and may advance cognitive health equity in aging.
Sections du résumé
BACKGROUND
This memory-clinic study joins efforts to study earliest clinical signs and symptoms of Alzheimer's disease and related dementias: subjective reports and objective neuropsychological test performance.
OBJECTIVE
The memory-clinic denoted two clinical "grey zones": 1) subjective cognitive decline (SCD; n = 107) with normal objective test scores, and 2) isolated low test scores (ILTS; n = 74) without subjective complaints to observe risk for future decline.
METHODS
Initial and annual follow-up clinical research evaluations and consensus diagnosis were used to evaluate baseline characteristics and clinical progression over 2.7 years, compared to normal controls (NC; n = 117).
RESULTS
The ILTS group was on average older than the NC and SCD groups. They had a higher proportion of people identifying as belonging to a minoritized racial group. The SCD group had significantly more years of education than the ILTS group. Both ILTS and SCD groups had increased risk of progression to mild cognitive impairment. Older age, minoritized racial identity, and baseline cognitive classification were risk factors for progression.
CONCLUSION
The two baseline risk groups look different from each other, especially with respect to demographic correlates, but both groups predict faster progression than controls, over and above demographic differences. Varied presentations of early risk are important to recognize and may advance cognitive health equity in aging.
Identifiants
pubmed: 35786652
pii: JAD215607
doi: 10.3233/JAD-215607
pmc: PMC9661415
mid: NIHMS1843172
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1377-1384Subventions
Organisme : NIMH NIH HHS
ID : K23 MH125074
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066468
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005133
Pays : United States
Références
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
J Geriatr Psychiatry Neurol. 2020 May;33(3):135-143
pubmed: 31409180
JAMA Netw Open. 2021 Jul 1;4(7):e2114606
pubmed: 34228130
PLoS One. 2019 Jul 15;14(7):e0219712
pubmed: 31306444
J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):159-65
pubmed: 16103044
Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):10-17
pubmed: 29240561
Neurology. 2020 Jan 28;94(4):e397-e406
pubmed: 31888974
Atherosclerosis. 1995 Jan 20;112(2):145-59
pubmed: 7772075
Neurology. 2018 Jan 16;90(3):126-135
pubmed: 29282327
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
BMJ. 1995 Jan 21;310(6973):170
pubmed: 7833759
J Am Geriatr Soc. 2020 Mar;68(3):535-543
pubmed: 31792940
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Cortex. 1987 Mar;23(1):59-72
pubmed: 3568706
Curr Opin Psychiatry. 2013 Jul;26(4):409-14
pubmed: 23454888
JAMA Neurol. 2020 Sep 1;77(9):1063-1064
pubmed: 32539100
Alzheimers Dement. 2012 May;8(3):172-9
pubmed: 22546351
Int Psychogeriatr. 2021 Aug;33(8):767-778
pubmed: 32301414
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
J Neurol. 2021 Jan;268(1):337-345
pubmed: 32804281
Alzheimers Dement. 2019 Feb;15(2):292-312
pubmed: 30555031
J Int Neuropsychol Soc. 2013 Jul;19(6):635-45
pubmed: 23552486
JAMA. 2020 Feb 25;323(8):764-785
pubmed: 32096857
Annu Rev Clin Psychol. 2017 May 8;13:369-396
pubmed: 28482688
J Clin Psychol. 1976 Jul;32(3):654-8
pubmed: 956433
Alzheimers Dement. 2020 Mar;16(3):552-560
pubmed: 31759879
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Gerontol Geriatr Med. 2015 Jan-Dec;1:
pubmed: 26925436
Front Aging Neurosci. 2021 Jun 11;13:684918
pubmed: 34177559
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248